Fusion protein capable of binding vegf-a and tnf-alpha

Abstract

The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.

What is claimed is: 
     
         1 . A fusion polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) TNFR2 component and VEGFR1 component operatively linked to (b) a multimerizing component, wherein the TNFR2 component comprising amino acid sequences of cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, or cysteine rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component comprises amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         2 . The fusion polypeptide  claim 1 , wherein the amino acid sequences of cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, or cysteine rich domain 4 of the extracellular domain of TNFR2 are located N-terminal to the Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         3 . The fusion polypeptide of  claim 1 , wherein the amino acid sequences of cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, or cysteine rich domain 4 of the extracellular domain of TNFR2 are located C-terminal to the Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         4 . The fusion polypeptide of  claim 1 , wherein the multimerizing component comprises an immunoglobulin domain. 
     
     
         5 . The fusion polypeptide of  claim 1 , wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG. 
     
     
         6 . The fusion polypeptide of  claim 1 , comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. 
     
     
         7 . The fusion polypeptide according to  claim 1 , which has been modified by acetylation or pegylation. 
     
     
         8 . A composition comprising the fusion polypeptide of  claim 1 , and a pharmaceutically acceptable carrier thereof. 
     
     
         9 . An isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component comprises a nucleotide sequence encoding the amino acid sequences of cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, or cysteine rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component comprises a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         10 . The isolated nucleic acid molecule of  claim 9 , wherein the nucleotide sequences encoding the cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, and cysteine rich domain 4 of the extracellular domain of TNFR2 are located upstream of the nucleotide sequence encoding the Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         11 . The isolated nucleic acid molecule of  claim 9 , wherein the nucleotide sequences encoding cysteine rich domain 1, cysteine rich domain 2, cysteine rich domain 3, and cysteine rich domain 4 of the extracellular domain of TNFR2 are located downstream of the nucleotide sequence encoding the Ig-like domain 2 of the extracellular domain of VEGFR1. 
     
     
         12 . An isolated nucleic acid molecule comprising a nucleotide sequence of (a) SEQ ID NO:1 or (b) SEQ ID NO:3, or a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) but which encodes identical amino acid sequence as expressed therefrom. 
     
     
         13 . A vector which comprises the nucleic acid molecule of  claim 9 . 
     
     
         14 . A host-vector system for the production of a fusion polypeptide which comprises the expression vector of  claim 13 , in a suitable host cell. 
     
     
         15 . A method of producing a fusion polypeptide which comprises growing cells of the host-vector system of  claim 14 , under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced. 
     
     
         16 . A method of inhibiting VEGF receptor ligand and TNF receptor ligand activities in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of  claim 1 . 
     
     
         17 . A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of  claim 1 . 
     
     
         18 . The method of  claim 16 , wherein VEGF receptor ligand and TNF receptor ligand activities cause diabetic and aged macular degerative retinophaties, rheumatoid arthritis, osteoarthritis, psoriasis, cancer, sclerosis, inflammatory bowel disease, polycystic kidney, ankylosing spondylitis, Crohn's disease, ulcerative colitis, atherosclerosis, and other acute and chronic inflammations. 
     
     
         19 . A method of treating retinopathy in a subject suffering from retinopathy, comprising administering the fusion polypeptide of  claim 1  to the subject. 
     
     
         20 . A method of treating rheumatoid arthritis in a subject suffering from rheumatoid arthritis, comprising administering the fusion polypeptide of  claim 1  to the subject.